TRCT
MRTX

Tower Research Capital (TRC)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,387
Closed -$140K – 6329
2023
Q4 		$140K Buy
2,387
+895
+60% +$50.3K ﹤0.01% 2368
2023
Q3 		$65K Sell
1,492
-13,278
-90% -$474K ﹤0.01% 2329
2023
Q2 		$534K Buy
14,770
+10,781
+270% +$444K 0.02% 934
2023
Q1 		$148K Sell
3,989
-7,693
-66% -$346K ﹤0.01% 1544
2022
Q4 		$529K Buy
11,682
+5,607
+92% +$363K 0.02% 669
2022
Q3 		$424K Sell
6,075
-8,721
-59% -$645K 0.01% 1273
2022
Q2 		$994K Buy
14,796
+5,846
+65% +$372K 0.02% 687
2022
Q1 		$736K Buy
8,950
+6,954
+348% +$711K 0.01% 932
2021
Q4 		$293K Buy
1,996
+756
+61% +$117K 0.01% 1496
2021
Q3 		$219K Sell
1,240
-2,935
-70% -$472K 0.01% 1734
2021
Q2 		$675K Buy
4,175
+1,861
+80% +$299K 0.02% 943
2021
Q1 		$396K Sell
2,314
-736
-24% -$146K 0.01% 1430
2020
Q4 		$670K Sell
3,050
-290
-9% -$62.7K 0.02% 784
2020
Q3 		$554K Buy
3,340
+957
+40% +$131K 0.01% 1571
2020
Q2 		$272K Buy
2,383
+2,358
+9,432% +$229K 0.01% 1538
2020
Q1 		$2K Sell
25
-615
-96% -$55.2K ﹤0.01% 2669
2019
Q4 		$82K Sell
640
-798
-55% -$77K 0.01% 1056
2019
Q3 		$112K Buy
+1,438
New +$135K 0.01% 1289
2019
Q2 		– Sell
-1,168
Closed -$86K – 4466
2019
Q1 		$86K Buy
1,168
+1,166
+58,300% +$79.3K 0.01% 1506
2018
Q4 		$0 Sell
2
-458
-100% -$18.3K ﹤0.01% 4502
2018
Q3 		$22K Buy
+460
New +$25.6K ﹤0.01% 2294
2018
Q2 		– Sell
-2,265
Closed -$70K – 4175
2018
Q1 		$70K Buy
2,265
+693
+44% +$19.2K 0.01% 1496
2017
Q4 		$28K Buy
+1,572
New +$24.4K ﹤0.01% 1809
2017
Q3 		– Sell
-16,793
Closed -$62K – 4237
2017
Q2 		$62K Buy
16,793
+16,765
+59,875% +$64.2K 0.01% 661
2017
Q1 		$0 Sell
28
-3,321
-99% -$18.2K ﹤0.01% 4099
2016
Q4 		$16K Sell
3,349
-16,865
-83% -$91.8K ﹤0.01% 2346
2016
Q3 		$134K Buy
20,214
+13,240
+190% +$70.5K 0.01% 679
2016
Q2 		$38K Buy
6,974
+6,474
+1,295% +$103K ﹤0.01% 1752
2016
Q1 		$11K Buy
500
+420
+525% +$9.39K ﹤0.01% 1894
2015
Q4 		$3K Buy
+80
New +$2.83K ﹤0.01% 3551
2015
Q1 		– Sell
-2,059
Closed -$38K – 5060
2014
Q4 		$38K Sell
2,059
-3,529
-63% -$59.5K ﹤0.01% 1196
2014
Q3 		$98K Buy
5,588
+4,356
+354% +$81.3K 0.01% 981
2014
Q2 		$25K Sell
1,232
-1,446
-54% -$27.9K ﹤0.01% 1715
2014
Q1 		$52K Buy
2,678
+787
+42% +$16.4K 0.01% 1065
2013
Q4 		$31K Buy
1,891
+1,591
+530% +$27.2K 0.01% 1862
2013
Q3 		$5K Buy
+300
New +$2.95K ﹤0.01% 3679

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Tower Research Capital (TRC)'s MRTX Position: Q1 2024 in Review

Tower Research Capital (TRC) sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 2,387 shares — an estimated $140K sold.

Tower Research Capital (TRC) first reported a position in MRTX in Q3 2013 and held it in 36 quarters. The position peaked at $994K in Q2 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Tower Research Capital (TRC) reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,387 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $140K.
  • Tower Research Capital (TRC) first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 36 quarters.
  • Tower Research Capital (TRC)'s Mirati Therapeutics, Inc. Common Stock position peaked at $994K in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.